Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Orladeyo?

See the DrugPatentWatch profile for Orladeyo

Orladeyo is a medication used to treat hereditary angioedema (HAE) [1]. It is taken orally once daily [1].

What is Hereditary Angioedema (HAE)?


Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling [1]. These attacks can affect the limbs, abdomen, face, and airway [1].

How Does Orladeyo Work?


Orladeyo's active ingredient is Berotralstat [1]. It is a plasma kallikrein inhibitor [1]. By inhibiting plasma kallikrein, it helps to prevent the swelling attacks associated with HAE [1].

When Can Orladeyo Be Used?


Orladeyo is approved for the prophylactic treatment of HAE in patients 12 years of age and older [1]. Prophylactic treatment means it is used to prevent attacks, rather than to treat an attack that is already happening [1].

What are the Potential Side Effects of Orladeyo?


Common side effects reported in clinical trials include gastrointestinal issues such as diarrhea, abdominal pain, and nausea [1]. Some patients may also experience upper respiratory tract infections, headache, or rash [1].

How is Orladeyo's Patent Status?


Information on Orladeyo's patent status, including expiry dates and any challenges, can be found on specialized patent tracking websites [2]. DrugPatentWatch.com is a resource that provides detailed data on drug patents and exclusivity [2].

What Other Treatments Are Available for HAE?


Besides Orladeyo, other HAE treatments include intravenous and subcutaneous self-administered therapies, as well as on-demand medications to treat acute attacks [1]. These can include C1 esterase inhibitor concentrates, kallikrein inhibitors, and bradykinin B2 receptor antagonists [1].

How Does Orladeyo Compare to Other HAE Treatments?


Orladeyo offers an oral, once-daily prophylactic option for HAE management [1]. This contrasts with some other long-term prophylactic treatments that require injections [1]. However, its efficacy and safety profile are distinct from other available therapies [1].

Sources:
[1] https://www.orladeyo.com/
[2] https://drugpatentwatch.com/



Other Questions About Orladeyo :

Biocryst pharmaceuticals orladeyo patent infringement lawsuit filing status march 2025? Biocryst pharmaceuticals sale european orladeyo berotralstat completion date? Biocryst pharmaceuticals orladeyo patent infringement lawsuit? Biocryst pharmaceuticals lawsuit generic drug companies orladeyo fda approval block status 2025? Orladeyo patent lawsuit 2025? Biocryst pharmaceuticals orladeyo patent infringement lawsuit 2025? Biocryst orladeyo patent sttlemembt?